RadioMedix & Curium Announce CMS Transitional Pass-Through Status for Detectnet™ (copper Cu 64 dotatate injection)

——— Download as PDF: English ——— (St. Louis, MO – December 9, 2020) – RadioMedix Inc. and its commercial partner Curium announced today that the Centers for Medicare & Medicaid Services (CMS) has granted Detectnet Transitional Pass-Through Status (code C9068) effective January 1, 2021. The descriptor for Detectnet will be: Copper Cu-64, dotatate, diagnostic, 1 millicurie. C9068 will be used to bill Detectnet for Medicare patients seen in the hospital outpatient department. “The response to Detectnet in the neuroendocrine community has been tremendous,” said Curium CEO, North America, Dan Brague. “Once in effect, this code will simplify the billing and reimbursement of Detectnet for our customers. We have been dedicated to helping patients in the neuroendocrine community for over 20 years and are excited to share this new code.” “The recent inclusion in a major Appropriate Use Criteria confirms the clinical utility of Detectnet in the neuroendocrine community,” said Ebrahim Delpassand, MD, CEO of RadioMedix. “The issuance of C9068 should further simplify the reimbursement process and help patients in need.” About Detectnet INDICATIONS Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. IMPORTANT RISK INFORMATION WARNINGS AND PRECAUTIONS Radiation Risk Diagnostic radiopharmaceuticals, including Detectnet, contribute to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration. Risk for Image Misinterpretation The uptake of copper Cu 64 dotatate reflects the level of somatostatin receptor density in NETs, however, uptake can also be seen in a variety of other tumors that also express somatostatin receptors. Increased uptake might also be seen in other non-cancerous pathologic conditions that express somatostatin receptors including thyroid disease or in subacute inflammation, or might occur as a normal physiologic variant (e.g. uncinate process of the pancreas).

The release as fetched from its publisher. curiumpharma.com ↗